| 倪文豪,徐丹颖,黄若冰,陈 岩,王红兵.替雷利珠单抗联合TC化疗方案治疗驱动基因阴性晚期肺腺癌的临床研究[J].,2025,(1):126-131 |
| 替雷利珠单抗联合TC化疗方案治疗驱动基因阴性晚期肺腺癌的临床研究 |
| Clinical Study of Tirelizumab Combined with TC Chemotherapy Regimen in the Treatment of Driver Gene Negative Advanced Lung Adenocarcinoma |
| 投稿时间：2024-07-15 |
| DOI：10.13241/j.cnki.pmb.2025.01.018 |
| 中文关键词: 替雷利珠单抗 TC化疗 驱动基因阴性 晚期肺腺癌 临床研究 |
| 英文关键词: Tirelizumab TC chemotherapy regimen Driver gene negative Advanced lung adenocarcinoma Clinical study |
| 基金项目:江苏省高层次卫生人才"六个一工程"项目（LGY2016041） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 摘要 目的：观察驱动基因阴性晚期肺腺癌患者在紫杉醇和卡铂（TC）化疗的基础上结合替雷利珠单抗治疗后的临床疗效。方法：按照随机数字表法将我院2021年8月~2023年8月期间收治的94例驱动基因阴性晚期肺腺癌患者分为对照组（TC化疗，47例）和观察组（替雷利珠单抗联合TC化疗方案治疗，47例）。对比两组疗效、血清肿瘤标志物、血清磷酸酰肌醇3激酶（PI3K）、蛋白激酶B（Akt）和不良反应。结果：和对照组比较，观察组客观缓解率、疾病控制率更高（P<0.05）。治疗后观察组癌胚抗原（CEA）、细胞角蛋白19片段抗原 21-1（CYERA21-1）、糖类抗原199 （CA199）、PI3K、Akt水平下降，且低于对照组（P<0.05）。两组不良反应发生率无差异（P>0.05）。结论：驱动基因阴性晚期肺腺癌患者在TC化疗的基础上结合替雷利珠单抗治疗后，可提高临床治疗效果，控制肿瘤疾病进展，降低肿瘤标志物水平，并可通过调节PI3K、Akt水平发挥治疗作用，且具有良好的安全性。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical efficacy of patients with driver gene negative advanced lung adenocarcinoma after treatment with paclitaxel and carboplatin (TC) chemotherapy combine with tirilizumab. Methods: 94 patients with driver gene negative advanced lung adenocarcinoma admitted to our hospital during August 2021~August 2023 were divided into control group (TC chemotherapy, 47 cases) and observation group (treated with tirilizumab combine with TC chemotherapy regimen, 47 cases)according to the randomized numerical table method. The efficacy, serum tumor markers, serum phosphoinositide 3 kinase (PI3K), protein kinase B (Akt) and adverse reactions were compared between two groups. Results: Compared with control group, the objective remission rate and disease control rate were higher in observation group (P<0.05). After treatment, the levels of carcinoembryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (CYERA21-1), cytokeratin 19 fragment antigen 21-1 (CYERA21-1), glycoconjugate antigen 199 (CA199), PI3K, and Akt decreased in observation group, and were lower than those in control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Driver gene negative advanced lung adenocarcinoma patients combine with tirelizzumab treatment on the basis of TC chemotherapy, which can improve the clinical treatment effect, control the progression of tumor disease, reduce the levels of tumor markers and exert therapeutic effects by regulating the levels of PI3K and Akt, and has good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
